RGT 100Alternative Names: ImOl 100; RGT100; RGT100-PEI
Latest Information Update: 12 Jan 2017
At a glance
- Originator Rigontec
- Class Antineoplastics; Gene therapies; Oligonucleotides; RNA
- Mechanism of Action DDX58 protein stimulants; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 03 Jan 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Recurrent) in Spain (Intralesional) (EudraCT2016-003028-22)
- 03 Jan 2017 Phase-I/II clinical trials in Solid tumours (Recurrent, Late-stage disease) in Spain (Intratumoural) (EudraCT2016-003028-22)